Mariano Barbacid Última actualización Mayo/2010
Mariano Barbacid was born in Madrid in 1949. He was awarded his PhD degree from the Universidad Complutense de Madrid in 1974. From 1974 – 1978 he trained as a Postdoctoral Fellow at the National Cancer Institute (NCI), Bethesda, Maryland, USA.
In 1978 he set up his own group to work on the molecular biology of human tumours. His work led to the isolation of the first human oncogene, H-Ras, in 1982. Other contributions of special relevance include the identification of Ras oncogenes as targets of chemical carcinogens (1984), the discovery of the Trk family of tyrosine kinase receptors as the signalling receptors for the NGF family of neurotrophic factors (1991) and the physiological role of the cell cycle Cdks (2003 – 2007).
He moved to the NCI campus in Frederick, Maryland (USA), as Head of the Developmental Oncology Section in 1984. In 1988, he joined the Bristol Myers-Squibb Pharmaceutical Research Institute in Princeton, New Jersey where he became Vice President of Oncology Drug Discovery. In 1998 he returned to Madrid to create and direct the CNIO (see Commentary in Cell, 129: 641-644, 2007).
Mariano Barbacid has authored 245 publications including 176 original articles and 24 invited reviews in refereed journals as well as 45 book chapters. The average impact factor of the 200 publications published in peer-reviewed journals is >12. His current Hirsch “h” factor is 86.
The relevance of his work has been recognised through several awards including the Young Investigator Award of the AACR (1986), the Steiner Prize (1988), the Ipsen Prize (1994), The Jimenez Díaz Award (2002), the Brupbacher Cancer Research Prize (2005), and the Medal of Honour of the International Agency for Research on Cancer (WHO) in 2007. He has been an EMBO Member since 1996.
http://www.cnio.es/es/grupos/plantillas/curriculum.asp?pag=14
In 1978 he set up his own group to work on the molecular biology of human tumours. His work led to the isolation of the first human oncogene, H-Ras, in 1982. Other contributions of special relevance include the identification of Ras oncogenes as targets of chemical carcinogens (1984), the discovery of the Trk family of tyrosine kinase receptors as the signalling receptors for the NGF family of neurotrophic factors (1991) and the physiological role of the cell cycle Cdks (2003 – 2007).He moved to the NCI campus in Frederick, Maryland (USA), as Head of the Developmental Oncology Section in 1984. In 1988, he joined the Bristol Myers-Squibb Pharmaceutical Research Institute in Princeton, New Jersey where he became Vice President of Oncology Drug Discovery. In 1998 he returned to Madrid to create and direct the CNIO (see Commentary in Cell, 129: 641-644, 2007).
Mariano Barbacid has authored 245 publications including 176 original articles and 24 invited reviews in refereed journals as well as 45 book chapters. The average impact factor of the 200 publications published in peer-reviewed journals is >12. His current Hirsch “h” factor is 86.
The relevance of his work has been recognised through several awards including the Young Investigator Award of the AACR (1986), the Steiner Prize (1988), the Ipsen Prize (1994), The Jimenez Díaz Award (2002), the Brupbacher Cancer Research Prize (2005), and the Medal of Honour of the International Agency for Research on Cancer (WHO) in 2007. He has been an EMBO Member since 1996.
http://www.cnio.es/es/grupos/plantillas/curriculum.asp?pag=14
